Skip to main content

Table 1 Baseline characteristics and HCV treatment outcomes compared between DM and non-DM patients

From: HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus

Baseline characteristics

Overall

n=1,588

DM

n=153

No DM

n=1,435

p value

Age at first assessment, mean (SD)

51.0 (13.6)

58.1 (9.6)

50.3 (13.5)

<0.001

Age category, n (%)

 ≤29

134 (8.4)

---

134 (9.3)

<0.001

 30-39

185 (11.7)

4 (2.6)

181 (12.6)

 40-49

291 (18.3)

24 (15.7)

267 (18.6)

 50-59

532 (33.5)

51 (33.3)

481 (33.5)

 60-69

365 (23.0)

59 (38.6)

306 (21.3)

 ≥70

81 (5.1)

15 (9.8)

66 (4.6)

Male sex, n (%)

1,010 (63.6)

108 (70.6)

902 (62.9)

0.059

Race, n (%)a

 Caucasian

1,064 (83.3)

106 (79.1)

958 (83.8)

0.205

 Black

79 (6.2)

13 (9.8)

66 (5.8)

 Asian

46 (3.6)

3 (2.2)

43 (3.8)

 Indigenous

69 (5.4)

9 (6.7)

60 (5.2)

 Hispanic

4 (0.3)

---

4 (0.4)

 Other

15 (1.2)

3 (2.2)

12 (1.0)

HCV RNA (IU/mL), mean (SD)

3.9x106 (13.3x106)

3.3 x106 (6.5x106)

3.9 x106 (13.9x106)

0.384

Genotype, n (%)a

 G1a

693 (51.4)

63 (46.1)

630 (52.0)

0.010

 G1b

113 (8.4)

15 (10.9)

98 (8.1)

 G1 (other subtypes)

46 (3.4)

2 (1.5)

44 (3.6)

 G2

99 (7.3)

15 (10.9)

84 (6.9)

 G3

293 (21.7)

26 (19.0)

267 (22.0)

 G4

52 (3.8)

15 (10.9)

37 (3.0)

 G5

3 (0.2)

1 (0.7)

2 (0.2)

 G6

8 (0.6)

---

8 (0.7)

 G mixed

42 (3.1)

---

42 (3.5)

Liver stiffness (kPa), mean (SD)

11.2 (11.8)

18.3 (15.6)

11.2 (11.1)

<0.001

CAP score (dB/mL), mean (SD)

246 (61)

262 (71)

244 (60)

0.001

Fibrosis Stage, n (%)a

 F0-F1

766 (52.1)

35 (24.6)

731 (55.0)

<0.001

 F2

197 (13.4)

16 (11.3)

181 (13.6)

 F3

172 (11.7)

25 (17.6)

147 (11.1)

 F4b

335 (22.8)

66 (46.5)

269 (20.3)

Year of assessment, n (%)

 2014

239 (15.0)

24 (15.7)

215 (15.0)

0.552

 2015

292 (18.4)

23 (15.0)

269 (18.7)

 2016

289 (18.2)

29 (18.9)

260 (18.1)

 2017

244 (15.4)

37 (24.2)

207 (14.4)

 2018

243 (15.3)

21 (13.7)

222 (15.5)

 2019

230 (14.5)

14 (9.2)

216 (15.1)

 2020

51 (3.2)

5 (3.3)

46 (3.2)

Baseline Laboratory Measures

 ALT (IU/L), mean (SD)

92 (104.2)

92 (101)

91 (105)

0.922

 AST (IU/L), mean (SD)

66 (66.9)

67 (72)

66 (66)

0.859

 Bilirubin (mmol/L), mean (SD)

11 (10.0)

13 (16.5)

11 (8.6)

0.157

 Hemoglobin (g/L), mean (SD)

140 (20)

137 (19)

140 (20)

0.031

 Platelets (109/L), mean (SD)

208 (81)

197 (88)

209 (80)

0.073

 Creatinine (umol/L), mean (SD)

77 (71)

95 (98)

75 (66)

0.016

Comorbidities

 HIV co-infection, n (%)

61 (3.8)

6 (3.9)

55 (3.8)

0.957

 Psychiatric condition, n (%)

751 (47.3)

77 (50.3)

674 (47.0)

0.429

 Hepatocellular carcinoma, n (%)a

37 (2.3)

9 (5.9)

28 (1.8)

0.001

 Chronic renal disease, n (%)a

34 (2.3)

20 (13.1)

14 (1.0)

<0.001

Socioeconomic determinants of health

 Immigrant, n (%)

269 (16.9)

44 (28.8)

225 (16.7)

<0.001

 Currently employed, n (%)

305 (28.6)

35 (26.5)

270 (28.9)

0.564

 Alcohol use history, n (%)

733 (55.7)

72 (47.1)

661 (56.9)

0.013

 Incarceration history, n (%)a

634 (49.0)

58 (38.2)

576 (50.4)

0.006

 IDU history, n (%)a

813 (62.4)

83 (54.6)

730 (63.5)

0.047

 Recreational drug use history, n (%)a

749 (58.2)

69 (45.4)

680 (59.9)

0.007

HCV treatment outcomes

 DAA therapy initiated, n (%)

  Yes

1,072 (67.5)

133 (86.9)

939 (65.4)

<0.001

  No

516 (32.5)

20 (13.1)

496 (34.6)

Crude SVR rate, n (%)

831/995 (83.6)

118/131 (90.1)

713/864 (86.8)

0.032

Post treatment testing SVR rate, n (%)

831/846 (98.2)

118/122 (96.7)

713/724 (98.5)

0.173

 Newly diagnosed hepatocellular carcinoma post treatment, n (%)

  12 months post treatment

3 (0.3)

1 (0.8)

2 (0.2)

---

  24 months post treatment

8 (0.8)

3 (2.3)

5 (0.6)

---

  1. aDenominator represents ntotal – nmissing data
  2. bCirrhosis by FibroScan defined as >12.5 kPa